SCHEMBL25329434

SCHEMBL25329434

N#Cc1ccc(N2CCC(c3ccc(OCCCBr)cc3)CC2)cc1C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
AR P10275 12/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25931177 0.97 AR (0.42) AR
SCHEMBL31131387 0.97 AR (0.42) AR
SCHEMBL25330466 0.96 AR (0.41) AR
SCHEMBL25330085 0.96 AR (0.41) AR
SCHEMBL25932428 0.94 AR (0.41) AR
SCHEMBL31131405 0.94 AR (0.41) AR
SCHEMBL31131401 0.94 AR (0.41) AR
SCHEMBL25932257 0.94 AR (0.41) AR
SCHEMBL25932268 0.94 AR (0.41) AR
SCHEMBL25936819 0.94 AR (0.41) AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4466260-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER Astrazeneca AB (SE) 2024-11-27 EP disclosed
CN-118574821-A Compounds and their use in the treatment of cancer 阿斯利康(瑞典)有限公司 2024-08-30 CN disclosed
WO-2023139199-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2023-07-27 WO disclosed
WO-2023139199-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2023-07-27 WO disclosed